DESCRIPTION 17pHSD Type 5 Inhibitor Technical Field [0001] The present invention relates to an indole compound having a pharmacological activity and a pharmaceutically acceptable salt thereof. The present invention also relates to a medicament or a pharmaceutical composition containing the indole compound or a pharmaceutically acceptable salt thereof described above as an active ingredient. Background Art [0002] Benign prostatic hyperplasia (BPH) is a disease mainly occurring in elder males aged 50 years or above and accompanying urinary disturbance, and its incidence rate increases as an increase in age. The number of patients with BPH in Japan has been constantly increasing in recent years with rapid aging of population structure (Non-patent Document 1). BPH remarkably deteriorates the quality of life of the aged males due to urinary disturbance, and it is an important disease in terms of medical economics since it is most frequently diagnosed and treated in medical practice in the department of urology. [0003] It has been found that two factors, that is, direct urethral compression due to hypertrophy of the prostate (mechanical obstruction) and elevation of intraurethral pressure due to overcontraction of the prostatic smooth muscle via the sympathetic nerve (functional obstruction), are simultaneously involved in urinary disturbance accompanying BPH. Drug therapy can deal with the both of the mechanisms, and 5 50:1 -* 20:1) to obtain 0.79 g of 7-chloro-4-methyl-1 H-indole-3-carboxylic acid as a beige solid. The compounds listed in Table 2 were obtained by the method similar to that described in Production Example 6. [0112] Production Example 10 To a solution of 1.01 g of methyl 5-(trifluoromethyl)-lH-indole-3-carboxylate in 12 mL of MeOH and 12 mL of THF, 6 mL of 1 M aqueous sodium hydroxide solution was added, and the resulting mixture was stirred at 80°C overnight. To the solution, 3 mL of 1 M aqueous sodium hydroxide solution was further added, and the resulting mixture was stirred at 80°C for 6 hours. To the solution, 9 mL of 1 M hydrochloric acid and 60 mL of water were added, the precipitated solid was collected by filtration, and the solid obtained was purified by silica gel column chromatography (chloroform-methanol = 100:1 -» 50:1 -» 20:1) and then washed with hexane to obtain 0.71 g of 5-(trifluoromethyl)-lH-indole-3-carboxylic acid as a cream-colored solid. FAB-: 228 [0114] Production Example 11 A solution of 5.21 g of l-chloro-4-methyl-2-nitrobenzene in 150 mL of THF was cooled to -50°C. To the solution was added 95 mL of 1 M vinylmagnesium bromide solution in THF while the inner temperature was kept at -30°C or lower, and the resulting mixture was stirred at -50°C for 2 hours. To the solution, 100 mL of the saturated aqueous ammonium chloride solution and 100 mL of 1 M hydrochloric acid were added, then the resulting mixture was warmed to room temperature and stirred for 15 minutes, and then extracted twice with 100 mL of ethyl acetate. The extract was washed with water and saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, and then the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate-hexane = 1:9) to obtain 2.69 g of 7-chloro-4-methylindole as a brown oil. Compounds listed in Table 3 were obtained by the method similar to that described in Production Example 11. [0115] The following Examples are described to explain the present invention in more detail, and the present invention will not restricted by the following Examples. Although the present invention is fully explained by way of the Examples, the person skilled in the art will appreciate that various alterations and modifications can naturally be made. Accordingly, these alterations and modifications are included in the present invention unless they depart from the scope of the present invention. [0117] Example 1 4.8 mg of indole-3-carboxylic acid was dissolved in 1 mL of tetrahydrofuran, 0.042 mL of n-butyllithium (1.58 M hexane solution) was added to the solution at 0°C, the resulting mixture was stirred for 30 minutes. Then 5.3 mg of benzenesulfonyl chloride was added to the mixture, and the resulting mixture was stirred at 0°C overnight. Water and chloroform were added to the mixture, the organic layer was separated and concentrated under reduced pressure, and the residue was purified by HPLC to obtain 1.0 mg of l-(phenylsulfonyl)-lH-indole-3-carboxylic acid. [0118] The HPLC conditions used for the purification will be described below. Column: SunFire (registered trademark) Particle size: 5 um, Inner diameter: 19 mm, Length: 100 mm Mobile phase: Solution A (= A sol), methanol Solution B (= B sol), 0.1 % aqueous formic acid solution [0119] [Table 4] mL of 1.60 M n-BuLi hexane solution was added dropwise while the inner temperature was kept at -50°C or lower by cooling in a dry ice-acetone bath, and the resulting mixture was stirred at the same temperature for 5 minutes, then at 0°C for 1 hour. The solution was cooled in a dry ice-acetone bath and a solution of 461 mg of 4-methoxybenzenesulfonyl chloride in 1 mL of THF was added dropwise. The solution was stirred at 0°C for 3 hours. To the solution, 20 mL of 5% aqueous potassium hydrogen sulfate solution and 40 mL of water were added in this order, and then the resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and then the solvent was evaporated under reduced pressure. To the residue was added 5 mL of ethyl acetate, and the resulting mixture was stirred at room temperature for 15 minutes. The white crystals formed were collected by filtration to obtain 509 mg of 1 -[(4-methoxyphenyl)sulfonyl] -1 H-indole-3 -carboxylic acid as a white solid. Example compounds listed in Tables 24 to 31 below were obtained by the methods similar to that described in Example 133. [0141] [0154] Example 210 a) Ethyl l-[(4-bromophenyl)sulfonyl]-lH-indole-2-carboxylate To a solution of 0.5 g of potassium t-butoxide and 0.1 g of 18-crown-6 in 3 mL of THF, a mixed solution of 0.7 g of ethyl 1 H-indole-2-carboxylate and 3 mL of THF was added, and the resulting mixture was stirred at room temperature for 30 minutes. The solution was cooled with ice, 1.13 g of 4-bromobenzenesulfonyl chloride was added, and the resulting mixture was stirred at room temperature for 5 hours. To the solution was added 60 mL of ethyl acetate, the resulting mixture was washed with water and saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, and then the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate-hexane = 1:5) to obtain 1.44 g of ethyl l-[(4-bromophenyl)sulfonyl]-lH-indole-2-carboxylate as a pale yellow syrup. FAB+:408,410 [0155] b) {l-[(4-bromophenyl)sulfonyl]-lH-indol-2-yl}methanol To a solution of 1.4 g of ethyl l-[(4-bromophenyl)sulfonyl]-lH-indole-2-carboxylate in 10 mL of THF, 7.6 mL of diisobutylalminum hydride-toluene solution was added at a temperature of -60°C or lower, and the resulting mixture was stirred under cooling in a dry ice-acetone bath for 5 hours and under ice cooling for 2 hours. After the solution was cooled to -70°C, 5 g of sodium sulfate decahydrate and 5 mL of methanol were added, the resulting mixture was warmed to room temperature, 50 mL of ethyl acetate and anhydrous sodium sulfate were added, insoluble matter was removed by filtration, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform) to obtain 0.97 g of {1 - [(4-bromophenyl)sulfonyl] -1 H-indol-2-yl} methanol as a pale violet solid. EI: 3 6 5, 367 [0156] c) l-[(4-bromophenyl)sulfonyl]-lH-indole-2-carbaldehyde To a solution of 0.93 g of {l-[(4-bromophenyl)sulfonyl]-lH-indol-2-yl}methanol and 1.1 mL of triethylamine in 10 mL of 1,2-dichloroethane, a solution of 1.21 g of sulfur trioxide-pyridine complex in 5 mL of DMSO was added under ice cooling, and the resulting mixture was stirred under ice cooling for 1 hour. The solution was poured into a mixed solution of 25 ml of ice water and 25 mL of saturated aqueous sodium chloride solution, the resulting mixture was extracted with 100 mL of ethyl acetate, the extract was washed with 5% aqueous potassium hydrogen sulfate solution, water and saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was washed with hexane to obtain 0.91 g of 1 -[(4-bromophenyl)sulfonyl]-lH-indole-2-carbaldehyde as a beige solid. FAB+: 364,366 [0157] d) (2E)-3 - {1 - [(4-bromophenyl)sulfonyl] -1 H-indol-2-yl} acrylic acid To a solution of 0.41 g of l-[(4-bromophenyl)sulfonyl]-lH-indole-2-carbaldehyde in 3 mL of pyridine, 0.35 g of malonic acid and 0.02 mL of piperidine were added, and the resulting mixture was stirred at 80°C for 3 hours. After the solution was allowed to cool, 50 mL of water and concentrated hydrochloric acid were added to adjust the pH to pH3, and the precipitated solid was collected by filtration and washed with ethanol to obtain 0.29 g of (2E)-3 - {1 - [(4-bromophenyl)sulfonyl]-1 H-indol-2-yl} acrylic acid as a pale yellow solid. Example compounds listed in Table 36 below were obtained by the method similar to that of Example 210. [0158] Example 212 To a solution of 180 mg of (2E)-3-[l-(phenylsulfonyl)-lH-indol-2-yl]acrylic acid in 3 mL of ethanol and 5 mL of methanol, 50 mg of 10% palladium-carbon (wet, water content 53%) was added, and the resulting mixture was stirred under hydrogen atmosphere (1 arm) at room temperature for 2 hours. The catalyst was removed from the solution, the solvent was evaporated under reduced pressure, and the residue was washed with ether to obtain 90 mg of 3-[l-(phenylsulfonyl)-lH-indol-2-yl]propanoic acid as a white solid. FAB-: 328 [0161] Example 213 a) Ethyl (2Z)-3-{ l-[(4-bromophenyl)sulfonyl]-lH-indol-2-yl}acrylate To a solution of 0.4 mL of ethyl di-o-tolylphosphonoacetate in 15 mL of THF was added 0.67 g of a 40% benzyltrimethylammonium hydroxide-methanol solution under cooling in a dry ice-acetone bath, and the resulting mixture was stirred at -70°C for 15 minutes. To the solution, a solution of 0.47 g of l-[(4-bromophenyl)sulfonyl]-lH-indole-2-carbaldehyde in 5 mL of THF was added, the resulting mixture was stirred at -70°C for 1.5 hours and under cooling in an ice-methanol bath for 1 hour. To the solution, 50 mL of saturated aqueous sodium chloride solution was added, the mixture was extracted with 100 mL of ethyl acetate, the extract was washed with water and saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate-hexane = 1:5) to obtain 0.53 g of ethyl (2Z)-3-{l-[(4-bromophenyl)sulfonyl]-lH-indol-2-yl}acrylate as a pale yellow syrup. ESI-: 432, 434 [0162] b) (2Z)-3 - {1 - [(4-bromophenyl)sulfonyl] -1 H-indol-2-yl} acrylic acid To a solution of 0.5 g of ethyl (2Z)-3-{l-[(4-bromophenyl)sulfonyl]-lH-indol-2-yl}acrylate in 4 mL of methanol and 0.4 mL of THF, 1.5 mL of a 1 M aqueous sodium hydroxide solution was added under ice cooling, and the resulting mixture was stirred under ice cooling for 2 hours and at room temperature for 3 hours. The solution was cooled with ice, 50 mL of water and 1.5 mL of 1 M hydrochloric acid were added, the mixture was extracted twice with 30 mL of chloroform, the extract was dried over anhydrous sodium sulfate, and then the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform -» chloroform-methanol = 100:1 —> 50:1) and then washed with hexane to obtain 0.28 g of (2Z)-3-{ l-[(4-bromophenyl)sulfonyl]-lH-indol-2-yl}acrylic acid as a pale yellow solid. FAB-: 404,406 [0163] Further, compounds listed in Tables 38 to 50 can be easily produced by the methods similar to those described in Examples above or applying the methods well known to the person skilled in the art based on these methods. These compounds are also included in the present invention. [0164] [Table 38] in Maniatis,T. et al., Molecular Cloning-A Laboratory Manual Cold Spring Harbor Laboratory, NY and the like (1982). In addition, a gene encoding human 17PHSD type5 and type3 described in 1 and 2 below, and human 17PHSD type5 and type3 may be obtained by the method described in Mol. Endocrinol, 1971-1984,11(13) (1997). [0178] 1. Isolation of gene encoding human 17|3HSD type 5 and purification of enzyme A full-length cDNA encoding human 17PHSD type 5 used in the pharmacological test of the present invention was obtained by the PCR method using a cDNA derived from a human lung cancer-derived cell line, A549 cells as a template. The nucleotide sequence of the obtained cDNA was analyzed by the dideoxyterminator method, and the clone matched with the known human 17J3HSD type 5 sequence (GenBank accession No. NM_003739) was selected. Escherichia coli BL21 was transformed with a plasmid containing the cDNA, cultured on a large scale, and the proteins were purified by using GSTrapFF column (Amersham) and PreScissionProtease (Amersham). The purification was performed in accordance with the instructions attached to the GSTrapFF column. [0179] 2. Isolation of gene encoding human 17|3HSD type 3 and purification of enzyme A full-length cDNA encoding human 17PHSD type 3 used in the pharmacological test of the present invention was obtained by the PCR method using a cDNA derived from human testis as a template. The nucleotide sequence of the obtained cDNA was analyzed by the dideoxyterminator method, and the clone matched with the known human 17pHSD type 3 sequence (GenBank accession No. BC034281) was selected. Subsequently, a human fetus kidney-derived cell line, 293 cells was transformed with a plasmid containing the cDNA, and the cells were collected 24 hours later. The collected cells were then disrupted in a phosphate buffer solution containing 5% glycerol (500 (aL per 100 mm-dish of a phosphate buffer solution (pH 7.4,200 mM) containing 5% glycerol) and centrifuged (16000 rpm, 5 min, 4°C), and the supernatant was used as an enzyme source. [0180] 3. Measurement of enzyme activities of human 17PHSD type 5 and type 3 Enzyme activity was measured referring to Trevor M. Penning, et al., Biochem. J., 351, 67-77, (2000). Specifically, using a 100 mM potassium phosphate buffer (pH 6.0), (1) the enzyme purified in above 1 at a final concentration of 10 ug/mL, (2) androstenedione at a final concentration of 300 nM, (3) NADPH at a final concentration of 200 uM and (4) a test substance at a final concentration of 3 uM were mixed to react at room temperature for 2 hours, and then the amount of testosterone produced was measured using DELFIA (registered trademark) Testosterone Reagents R050-201 (PerkinElmer). The measurement was performed in accordance with the attached instructions. The amount of reduction of testosterone production in the presence of the compound was obtained as a relative value with respect to the amount of testosterone in the absence of the enzyme set at 0% and the amount of testosterone produced in the absence of the compound set at 100%. Then, IC50 values were calculated by the Logistic regression method. [0181] The IC50 values of inhibitory activity against human 17{3HSD type 5 and type 3 of the Example compounds included in the compounds of the present invention are shown in Table 51. In addition, the IC50 values of inhibitory activity against human 17PHSD type 5 of the compounds described in Non-patent Document 19 and confirmed to be effective for Ehrlich ascites tumor are shown in Comparative Examples (1) and (2) in Table 51. The structural formula of the compounds in Comparative Examples (1) and (2) are shown below. [0182] [formula 33] As shown by the test results above, the compounds of the present invention represented by formula (I) and/or formula (II) and/or formula (III) scarcely have inhibitory activity against human 17|3HSD type 3 and have inhibitory activity selective to human 17J5HSD type 5. In addition, the compounds of Comparative Examples (1) and (2) that are known to be effective for Ehrlich ascites tumor scarcely exhibited 170HSD type 5 inhibitory activity. [0185] 4. Measurement of concentrations of human 17PHSD type 5 inhibitor compounds in mouse tissues The concentrations in plasma and in prostate were measured after oral administration of a test substance. Male 8 to 15-week old ICR mice were used, and a solution or suspension obtained by adding 1 N NaOH solution and water in an equivalent amount to a test substance and stirring was used as an administration solution. The administration solution was administered orally once to mice, and after 2 hours, blood and a prostate were collected under ether anesthesia. The prostate was frozen and stored at -80°C until measurement. The blood was centrifuged (3000 rpm, 15 min, 4°C) after the addition of a minor amount of heparin, and the upper layer was collected as plasma and frozen and stored at -80°C until measurement. 0.1 mL of the plasma was subjected to protein degeneration with 0.1 mL of acetonitrile and then centrifuged (15000 rpm, 7 min, 4°C) to remove proteins and the supernatant thus obtained was used as an HPLC sample. The prostate was homogenized in a phosphate buffer solution (200 mM, pH 7.4, 0.5 mL), and then the whole volume was added to 3 mL of t-butyl methyl ether to perform extraction. The solvent was evaporated in a stream of nitrogen (15 min, 45°C). The residue was resuspended in a Tris buffer solution (12.5 mM, pH 7.4,0.3 mL) containing 2% BSA, and an equal volume of acetonitrile (0.3 mL) was added. Protein was removed as in the case of plasma and the supernatant was used as an HPLC measurement sample. Measurement was performed by an ordinary method using liquid chromatography (HPLC). The results are described in Table 52. [0186] Column: STR ODS-II (registered trademark), particle size: 5 um, inner diameter: 4.6 mm, length: 150 mm, joint type: Waters Mobile phase: 20 mM ammonium acetate:acetonitrile = 7:3 or 17 mM ammonium acetate:acetonitrile = 6:4 Flow rate: 1 mL/min Column temperature: 40°C Injection volume: 50 uL [0187] [Table 52] Ex Dose(mg/kg) Cone (plasmaXuM) Cone (prostateXuM) 1 30 17.0 5.3 100 57.4 13.3 300 145.1 47.4 144 100 38.5 7.2 300 79.1 24.8 190 300 225.5 37.4 155 100 88.4 23.0 175 100 83.8 8.6 163 100 88.8 19.1 192 100 57.3 9.4 300 126.1 24.9 187 100 69.7 12.2 Dose: dose, Cone (plasma): concentration in the plasma, Cone (prostate): concentration in prostate [0188] As shown by the test results above, the compounds of formula (I) and/or (II) and/or formula (III) show good oral drug absorption and prostate distribution. Since the compounds of formula (I) and/or (II) and/or formula (III) have very weak inhibitory activity against human 17PHSD type 3, it is expected to suppress intracrine testosterone synthesis selectively in the prostate by their selective inhibitory effect against 17|3HSD type 5 without affecting biosynthesis of testosterone derived from human 17PHSD type 3 in the testes, thus useful especially for treating and/or preventing benign prostatic hyperplasia and prostatic cancer without adverse drug reactions. [0189] A pharmaceutical composition containing the compound of formula (I) and/or formula (II) and/or formula (III) or a pharmaceutically acceptable salt thereof as an active ingredient can be prepared using a carrier, an excipient, and other additives that are generally used for formulation. [0190] Administration may be any of oral administration using tablets, pills, capsules, granules, powders, liquids and the like, or parenteral administration using injections such as intravenous injection, intramuscular injection and the like, suppositories, percutaneous preparations, nasal preparations, inhalation preparations or others. The dose is determined accordingly taking symptoms, age and sex of a subject and the like into consideration depending on each case. The dose is generally around 0.001 to 100 mg/kg/day for an adult in the case of oral administration, and the daily dose is administered in a single dose or 2 to 4 divided doses. When it is administered intravenously according to symptoms, it is administered one to several times a day at a dose in the range of 0.0001 to 10 mg/kg/dose for an adult. In the case of inhalation, it is administered one to several times* a day at a dose in the range of 0.0001 to 1 mg/kg/dose for an adult. [0191] As a solid composition for oral administration according to the present invention, tablets, powder, granules and the like are used. In such solid composition, one or more active ingredients are mixed with at least one inactive excipient, for example, lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinyl pyrrolidone, magnesium aluminometasilicate and the like. The composition may contain, according to an ordinary method, inactive additives, for example, lubricants such as magnesium stearate and the like, disintegrants such as sodium carboxymethyl starch and the like, and solubilization assisting agents. Tablets or pills may be sugar-coated or coated with a gastric dissolving or enteric coating, if necessary. [0192] A liquid composition for oral administration includes pharmaceutically acceptable emulsion, solution, suspension, syrup, elixir and the like, and contains inert solvents used in general, for example, purified water and ethanol. The composition may contain, in addition to the inert solvent, auxiliary agents such as solubilizing agents, moistening agents, and suspending agents; sweeteners; flavoring agents; fragrances; and preservatives. [0193] An injection for parenteral administration includes sterile aqueous or non-aqueous solution, suspension, and emulsion. Examples of aqueous solvents include, for example, distilled water for injection and physiological saline solution. Examples of non-aqueous solvents include, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, polysorbate 80 (Pharmacopoeia name) and the like. The composition may further contain tonicity agents, preservatives, moistening agents, emulsifiers, dispersing agents, stabilizers, and solubilizing agents. The composition is sterilized by, for example, filtration through a bacteria-retaining filter, incorporation of a bactericide or irradiation. In addition, a sterile solid composition may be first produced, and then dissolved or suspended in sterile water or sterile solvent for injection before use, and then used. [0194] Transmucosal preparations such as inhalation preparations, transnasal preparations and the like are used in a solid, liquid, or semisolid form, and can be produced by the method conventionally known. For example, excipients such as lactose and starch, and further, pH adjusting agents, preservatives, surfactants, lubricants, stabilizers, and thickeners and the like may be appropriately added. For administration, an appropriate device for inhalation or insufflation may be used. For example, using known devices such as a metered dose inhalation device or spray device, the compound can be administered alone or as powder of a formulated mixture or a solution or suspension in combination with pharmaceutically acceptable carriers. A dry powder inhaler and the like may be for single dose or multiple dose, and dry powder or powder-containing capsule may be used. Alternatively, a pressurized aerosol spray and the like using an appropriate gas, such as propellants, for example, chlorofluoroalkane, hydrofluoroalkane, carbon dioxide or the like. [0195] In producing suppositories, a low melting point wax, for example, a fatty acid 'lyceride mixture or cocoa butter is melted, and an active ingredient is added and dispersed homogeneously by stirring. After that, the mixture is injected into an ippropriate mold and cooled for solidification. Liquid preparations include solution, suspension, retention enema and emulsion, for example, a water or aqueous propylene glycol solution. [ndustrial Applicability ;0196] Since the compound, an active ingredient of the medicament of the present invention, has a selective inhibitory effect against 17PHSD type 5 and a superior pharmacological effect based thereon, the pharmaceutical composition according to the present invention is useful as a therapeutic and/or preventive agent for diseases issociated with 17PHSD type 5, particularly prostatic cancer, benign prostatic lyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal lypertrophy, polycystic ovary syndrome, breast cancer, lung cancer, endometriosis, eiomyoma or the like. represents an aryl, cycloalkyl or heterocyclic group; Raaa, which is the same or different, represents hydrogen, lower alkyl, halogen, cyano, lower alkenyl, halogen-substituted lower alkyl, lower alkyl-O-, cyano lower alkyl-O-, halogen-substituted lower alkyl-O-, aryl, heteroaryl, aryl-O-, heteroaryl-O-, aryl lower alkyl, acyl-O-, acyl, heteroaryl lower alkyl-O-, lower alkylthio, lower alkylsulfonyl, oxo, nitro, amino, mono-lower alkylamino, di-lower alkylamino, acylamino or arylamino, in which the aryl, the heteroaryl, and the aryl and the heteroaryl moieties of each of the aryl-O-, heteroaryl-O-, heteroaryl lower alkyl-O-, aryl lower alkyl and arylamino in the Raaa may be substituted by lower alkyl(s), lower alkyl-O-(s), halogen(s) or halogen-substituted lower alkyl(s); R111, R222, R333, R444, R555 and R666 represent hydrogen or an appropriate substituent, in which at least one of the R111, R222, R333, R444, R555 and R666 represents carboxy, carboxy-substituted lower alkyl or carboxy-substituted lower alkenyl, and any adjacent two groups of R333, R444, R555 and R666 together may form a lower alkylene dioxy group; a double line of a solid line and a dotted line represents a single bond or a double bond; and p represents an integer of 1 to 15. 2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein L is a bond; [formula 36] © represents phenyl or naphthyl; R222 represents carboxy; Raaa, which is the same or different, represents hydrogen or halogen; Rm, R333, R444, R555 and R666 represent hydrogen; a double line of a solid line and a dotted line represents a single bond; and p represents an integer of 1 to 3. 3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein L is a bond; [formula 37] ® represents phenyl; Raaa, which is the same or different, represents hydrogen or halogen; Rnl represents carboxy-substituted lower alkyl or carboxy-substituted lower alkenyl; R222, R333, R444, R555 and R666 represent hydrogen; a double line of a solid line and a dotted line represents a double bond; and p represents an integer of 1 to 3. 4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein L is a bond; [formula 38] © represents phenyl; Raaa, which is the same or different, represents hydrogen or halogen; R444 represents carboxy-substituted lower alkyl or carboxy-substituted lower alkenyl; R111, R222, R333, R555 and R666 represent hydrogen; a double line of a solid line and a dotted line represents a double bond; and p represents an integer of 1 to 3. 5. A pharmaceutical composition comprising the compound according to claim 1 represented by formula (I). 6. A therapeutic agent and/or a preventive agent for a disease associated with 170HSD type 5, comprising the compound according to claim 1 represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. 7. A therapeutic agent and/or preventive agent for prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma, comprising the compound according to claim 1 represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. 8. Use of the compound according to claim 1 represented by formula (I) or a pharmaceutically acceptable salt thereof for producing a medicament for a treatment and/or prevention of a disease associated with 17PHSD type 5. 9. Use of the compound according to claim 1 represented by formula (I) or a pharmaceutically acceptable salt thereof for producing a medicament for a treatment and/or prevention of prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma. 10. A therapeutic and/or preventive method for a disease associated with 170HSD type 5, comprising administering an effective amount of the compound according to claim 1 represented by formula (I) or a pharmaceutically acceptable salt thereof to a patient. 11. A method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma, comprising administering an effective amount of the compound according to claim 1 represented by formula (I) or a pharmaceutically acceptable salt thereof to a patient. 12. An inhibitor of 17pHSD type 5, comprising the compound according to claim 1 represented by formula (I) or a pharmaceutically acceptable salt thereof. 13. A commercial package, comprising a pharmaceutical composition containing the compound according to claim 1 represented by formula (I) or a pharmaceutically acceptable salt thereof; and a description that the compound represented by formula (I) or a pharmaceutically acceptable salt thereof is capable of being used or should be used for a treatment and/or prevention of prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma. 14. A therapeutic agent and/or a preventive agent for a disease associated with 17PHSD type 5, comprising a compound represented by formula (II) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein T represents lower alkylene, lower alkenylene, -O-lower alkylene, lower alkylene-O- or a bond, in which each of the groups may be substituted by aryl(s); [formula 40] ® represents an aryl, cycloalkyl or heterocyclic group; Raa, which is the same or different, represents hydrogen, lower alkyl, halogen, cyano, lower alkenyl, halogen-substituted lower alkyl, lower alkyl-O-, cyano lower alkyl-O, halogen-substituted lower alkyl-O-, aryl, heteroaryl, aryl-O-, heteroaryl-O-, aryl lower alkyl, acyl-O-, acyl, heteroaryl lower alkyl-O-, lower alkylthio, lower alkylsulfonyl, oxo, nitro, amino, mono-lower alkylamino, di-lower alkylamino, acylamino or arylamino, in which the aryl, the heteroaryl, and the aryl and the heteroaryl moieties of each of the aryl-O-, heteroaryl-O-, heteroaryl lower alkyl-O-, aryl lower alkyl and arylamino in the Raa may be substituted by lower alkyl(s), lower alkyl-O-(s), halogen(s) or halogen-substituted lower alkyl(s); R22, R33, R44, R55 and R66 represent hydrogen or an appropriate substituent, in which at least one of R22, R33, R44, R55 and R66 represents carboxy; and m represents an integer of 1 to 15. 15. A therapeutic agent and/or preventive agent for prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma, comprising the compound (II) according to claim 14 or a pharmaceutically acceptable salt thereof. 16. Use of the compound according to claim 14 represented by formula (II) or a pharmaceutically acceptable salt thereof for producing a medicament for a treatment and/or prevention of a disease associated with 17J3HSD type 5. 17. Use of the compound according to claim 14 represented by formula (II) or a pharmaceutically acceptable salt thereof for producing a medicament for a treatment and/or prevention of prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma. 18. A therapeutic and/or preventive method for a disease associated with 17PHSD type 5, comprising administering an effective amount of the compound according to claim 14 represented by formula (II) or a pharmaceutically acceptable salt thereof to a patient. 19. A method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma, comprising administering an effective amount of the compound according to claim 14 represented by formula (II) or a pharmaceutically acceptable salt thereof to a patient. 20. An inhibitor of 17PHSD type 5, comprising the compound according to claim 14 represented by formula (II) or a pharmaceutically acceptable salt thereof. 21 A commercial package, comprising a pharmaceutical composition containing the compound according to claim 14 represented by formula (II) or a pharmaceutically acceptable salt thereof; and a description that the compound represented by formula (II) or a pharmaceutically acceptable salt thereof is capable of being used or should be used for a treatment and/or prevention of prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma. 22. A compound or a pharmaceutically acceptable salt thereof, wherein A represents lower alkylene, lower alkenylene, -O-lower alkylene, lower alkylene-O- or a bond, in which each of the groups may be substituted by aryl(s); [formula 42] ® represents an aryl, cycloalkyl or heterocyclic group; Ra, which is the same or different, represents hydrogen, lower alkyl, halogen, cyano, lower alkenyl, halogen-substituted lower alkyl, lower alkyl-O-, cyano lower alkyl-O-, halogen-substituted lower alkyl-O-, aryl, heteroaryl, aryl-O-, heteroaryl-O-, aryl lower alkyl, acyl-O-, acyl, heteroaryl lower alkyl-O-, lower alkylthio, lower alkylsulfonyl, oxo, nitro, amino, mono-lower alkylamino, di-lower alkylamino, acylamino or arylamino, in which the aryl, the heteroaryl, and the aryl and the heteroaryl moieties of each of the aryl-O-, heteroaryl-O-, heteroaryl lower alkyl-O-, aryl lower alkyl and arylamino in the Ra may be substituted by lower alkyl(s), lower alkyl-O-(s), halogen(s) or halogen-substituted lower alkyl(s); R2 to R6 represent hydrogen or an appropriate substituent, in which at least one ofR2to R6 represents carboxy, and any adjacent two groups of R3 to R6 together may form a lower alkylene dioxy group; and n represents an integer of 1 to 15; provided that when R2 is carboxy, R3, R4, R5 and R6 are hydrogen, [formula 43] © is 1-naphthyl, A is a bond and n is 1; Ra is a group other than 4-methoxy: when R2 is carboxy, and R3, R4, R5 and R6 are hydrogen, [formula 44] © is phenyl, A is a bond, and n is 1; Ra is a group other than hydrogen and 4-methyl: and when n is 2, a combination of two Ra's is selected from combinations of groups other than a combination of 4-methyl and 3-nitro and a combination of 3-methoxy and 4-methoxy: when R3 is carboxy, R2, R4, R5 and R6 are hydrogen, [formula45] © is phenyl, A is a bond, and n is 1; Ra is a group other than 4-methyl: when R4 is carboxy, R2, R5 and R6 are hydrogen, R3 is 2-bromophenyl, [formula 46] © is 2-thienyl, A is a bond, and n is 1; the Ra is a group other than hydrogen: when R4 is carboxy, R2, R3, R5 and R6 are hydrogen, [formula 47] © is phenyl, A is a bond, and n is 1; Ra is a group other than hydrogen: when R4 is carboxy, R3, R5 and R6 are hydrogen, R2 is 3-methoxycarbonyl-3-hydroxyacryloyl, [formula 48] © is phenyl, A is a bond, and n is 1; Ra is a group other than hydrogen: when R4 is carboxy, R3, R5 and R6 are hydrogen, R2 is 3-carboxy-3-hydroxyacryloyl, [formula 49] © is phenyl, A is a bond, and n is 1; Ra is a group other than hydrogen: when R4 is carboxy, R3, R5 and R6 are hydrogen, R2 is acetyl, [formula 50] © is phenyl, A is a bond, and n is 1; Ra is a group other than hydrogen: when R5 is carboxy, R2 is methyl, R3, R4 and R6 are hydrogen, [formula 51] © is phenyl, A is a bond, and n is 1; Ra is a group other than 4-methyl: when R5 is carboxy, R2, R3, R4 and R6 are hydrogen, [formula 52] © is 8-quinolinyl, A is a bond, and n is 1; Ra is a group other than hydrogen. 23. The compound according to claim 22 or a pharmaceutical^ acceptable salt thereof, wherein A is lower alkylene which may be substituted by phenyl(s), lower alkylene-O- which may be substituted by phenyl(s), lower alkenylene or a bond; [formula 53] © represents phenyl, naphthyl, benzothiazolyl, dibenzo[b,d]furanyl, thienyl, pyrazolyl, benzothienyl, imidazolyl, pyridyl, 2,1,3,-benzothiadiazolyl, isoquinolyl, cyclopropyl, cyclohexyl or 3,4-dihydro-2H-1,4-benzoxazinyl; Ra, which is the same or different, represents hydrogen, lower alkyl, halogen, cyano, lower alkenyl, halogen-substituted lower alkyl, lower alkyl-O-, cyano lower alkyl-O-, halogen-substituted lower alkyl-O-, phenyl, oxadiazolyl, phenoxy, pyridyloxy, pyridylcarbonyl, pyrrolidinylsulfonyl, thiazolyl lower alkyl-O-, lower alkylsulfonyl, nitro or di-lower alkylamino, in which the phenyl and oxadiazolyl and the phenyl, the pyridyl and the thiazolyl moieties of each of the phenoxy, pyridyloxy, pyridylcarbonyl and thiazolyl lower alkyl-O- may be substituted by lower alkyl(s), lower alkyl-O-(s) or halogen(s); R2 to R6 represent hydrogen, lower alkyl, lower alkyl-O-, benzyloxy, hydroxy, halogen, halogen-substituted lower alkyl, carboxy or any adjacent two groups of R to R together form lower alkylene dioxy group, provided that at least one of R to R represents carboxy; and n represents an integer of 1 to 3. 24. The compound according to claim 23 or a pharmaceutically acceptable salt thereof, wherein either one of R orR iscarboxy. 25. The compound according to claim 24 or a pharmaceutically acceptable salt thereof, wherein A is lower alkenylene or a bond; [formula 54] © represents phenyl, naphthyl, pyridyl or isoquinolyl; R represents carboxy; Ra, which is the same or different, represents hydrogen, lower alkyl, halogen, cyano, halogen-substituted lower alkyl, lower alkyl-O-, halogen-substituted lower alkyl-O- or lower alkylsulfonyl: and R3 to R6 represent hydrogen, lower alkyl, lower alkyl-O-, benzyloxy, hydroxy, halogen, halogen-substituted lower alkyl, or a lower alkylene dioxy group formed from any adjacent two groups. 26. The compound according to claim 25 or a pharmaceutically acceptable salt thereof, wherein A is a bond; [formula 55] © represents phenyl; Ra, which is the same or different, represents hydrogen or halogen; and R3 to R6 represent hydrogen, lower alkyl, lower alkyl-O-, or halogen. 27. The compound according to claim 26 or a pharmaceutically acceptable salt thereof, which is 1-[(4-bromophenyl)sulfonyl]-lH-indole-3-carboxylic acid, 4-methoxy-1-(phenylsulfonyl)-1 H-indole-3-carboxylic acid, 5 -methyl-1 -(phenylsulfonyl)-1 H-indole-3 -carboxylic acid, 5-fluoro-l-(phenylsulfonyl)-lH-indole-3-carboxylic acid, 7-fluoro-l-(phenylsulfonyl)-lH-indole-3-carboxylic acid, l-[(4-bromophenyl)sulfonyl]-7-chloro-lH-indole-3-carboxylicacid, 7-chloro-1 -(phenylsulfonyl)-1 H-indole-3 -carboxylic acid, or 5-chloro-1 -(phenylsulfonyl)-1 H-indole-3 -carboxylic acid. 28. The compound according to claim 22 or a pharmaceutical^ acceptable salt thereof, wherein A is lower alkylene, -O-lower alkylene, lower alkylene-O- or a bond, in which each of the groups may be substituted by aryl(s); [formula 56] © represents aryl, cycloalkyl or heterocyclic group; Ra, which is the same or different, represents hydrogen, lower alkyl, halogen, cyano, lower alkenyl, halogen-substituted lower alkyl, lower alkyl-O-, cyano lower alkyl-O-, halogen-substituted lower alkyl-O-, aryl, heteroaryl, aryl-O-, heteroaryl-O-, aryl lower alkyl, acyl-O-, acyl, heteroaryl lower alkyl-O-, lower alkylthio, oxo, nitro, amino, mono-lower alkylamino, di-lower alkylamino, acylamino, or arylamino, in which the aryl and heteroaryl and the aryl and the heteroaryl moieties of each of the aryl-O-, heteroaryl-O-, heteroaryl lower alkyl-O-, aryl lower alkyl, and arylamino in the Ra may be substituted by lower alkyl(s), lower alkyl-O-(s), halogen(s), or halogen-substituted lower alkyl(s); R to R represent hydrogen or an appropriate substituent, in which at least one of the R to R6 represents carboxy; and n represents an integer of 1 to 15. 29. The compound according to claim 22 or a pharmaceutically acceptable salt thereof, wherein A is a bond; [formula 57] © represents phenyl or naphthyl; Ra, which is the same or different, represents hydrogen, lower alkyl, halogen, cyano, halogen-substituted lower alkyl, lower alkyl-O, halogen-substituted lower alkyl-O- or lower alkylsulfonyl; R3 represents carboxy; and R2 and R4 to R6 represent hydrogen, lower alkyl, lower alkyl-O-, benzyloxy, hydroxy, halogen, or halogen-substituted lower alkyl. 30. The compound according to claim 22 or a pharmaceutically acceptable salt thereof, wherein A is a bond; [formula 58] © represents phenyl or naphthyl; Ra, which is the same or different, represents hydrogen, lower alkyl, halogen, cyano, halogen-substituted lower alkyl, lower alkyl-O-, halogen-substituted lower alkyl-O-, or lower alkylsulfonyl; R4 represents carboxy; and R2 to R3 and R5 to R6 represent hydrogen, lower alkyl, lower alkyl-O-, benzyloxy, hydroxy, halogen, or halogen-substituted lower alkyl. 31. The compound according to claim 22 or a pharmaceutically acceptable salt thereof, wherein A is a bond; [formula 59] © represents phenyl or naphthyl; Ra, which is the same or different, represents hydrogen, lower alkyl, halogen, cyano, halogen-substituted lower alkyl, lower alkyl-O-, halogen-substituted lower alkyl-O-, or lower alkylsulfonyl; R5 represents carboxy; and R to R4 and R6 represent hydrogen, lower alkyl, lower alkyl-O-, benzyloxy, hydroxy, halogen or halogen-substituted lower alkyl. 32. The compound according to claim 22 or a pharmaceutically acceptable salt thereof, wherein A is a bond; [formula 60] © represents phenyl or naphthyl; Ra, which is the same or different, represents hydrogen, lower alkyl, halogen, cyano, halogen-substituted lower alkyl, lower alkyl-O-, halogen-substituted lower alkyl-O-, or lower alkylsulfonyl;R6 represents carboxy; and R to R represent hydrogen, lower alkyl, lower alkyl-O-, benzyloxy, hydroxy, halogen, or halogen-substituted lower alkyl. 33. A pharmaceutical composition, comprising the compound according to claim 22 represented by formula (III). 34. A therapeutic agent and/or preventive agent for a disease associated with 17PHSD type 5, comprising the compound according to claim 22 represented by formula (III) or a pharmaceutically acceptable salt thereof as an active ingredient. 35. A therapeutic agent and/or preventive agent for prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma, comprising the compound according to claim 22 represented by formula (III) or a pharmaceutically acceptable salt thereof as an active ingredient. 36. Use of the compound according to claim 22 represented by formula (III) or a pharmaceutically acceptable salt thereof for producing a medicament for the a treatment and/or prevention of a disease associated with 17PHSD type 5. 37. Use of the compound according to claim 22 represented by formula (III) or a pharmaceutically acceptable salt thereof for producing a medicament for a treatment and/or prevention of prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma. 38. A method for treating a disease associated with 17J3HSD type 5, comprising administering an effective amount of the compound according to claim 22 represented by formula (III) or a pharmaceutically acceptable salt thereof to a patient. 39. A method for treating and/or preventing prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma, comprising administering an effective amount of the compound according to claim 22 represented by formula (III) or a pharmaceutically acceptable salt thereof to a patient. 40. An inhibitor for 170HSD type 5, comprising the compound according to claim 22 represented by formula (III) or a pharmaceutically acceptable salt thereof. 41. A commercial package, comprising a pharmaceutical composition containing the compound according to claim 22 represented by formula (III) or a pharmaceutically acceptable salt thereof, and a description that the compound represented by formula (III) or a pharmaceutically acceptable salt thereof is capable of being used or should be used for a treatment and/or prevention of prostatic cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, endometriosis, lung cancer or leiomyoma.